BCG Versus VCN: The Antigenicity and the Adjuvant Effect of Both Compounds

  • F. R. Seiler
  • H.-H. Sedlacek
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 75)

Abstract

Enzymatically active Vibrio cholerae neuraminidase (VCN) acts as an adjuvant when it is combined with an antigen. This has been demonstrated for bacterial, viral, protein, and cellular antigens and was found for the humoral, but more pronounced for the cellular immune response. In this study, the adjuvant activity of VCN for live BCG is discussed. Live BCG itself is regarded as a rather potent immunostimulator. A total of 6.5 mU of VCN, being most effective as derived from previous adjuvant experiments, was combined with 106 or 107 live BCG and injected IV into mice. Booster injections were given on day 12. Challenge was administered in the footpad on day 17 either with 6.5 mU VCN or with 5 × 104 or 5 × 106 dead BCG. Footpad swelling was recorded 24 h after challenge. After clinical examination, mice were bled and antibodies against BCG and VCN were measured. The results show that VCN specifically enhances the cellular, not the humoral, immune reaction against BCG, while BCG is unable specifically to enhance immune reaction against VCN. However, BCG unspecifically stimulates the cellular reaction of the organism against an antigen, primarily injected, subsequent to BCG for instance, against VCN.

Keywords

Leukemia Methacrylate Glutaraldehyde Vibrio Hydroxyethyl Methacrylate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burnet FM (1957) Cancer — a biological approach. IV. Practical applications. Br Med J 1:844–847Google Scholar
  2. 2.
    Currie GA (1972) Eighty years of immunotherapy: A review of immunological methods used for the treatment of human cancer. Br J Cancer 26:141–153PubMedCrossRefGoogle Scholar
  3. 3.
    Holland JF, Bekesi JG, Cuttner J, Glidewell O (1977) Chemoimmunotherapy in acute myelocytic leukemia. Isr J Med Sci 13:694–700PubMedGoogle Scholar
  4. 4.
    Knop J, Sedlacek HH, Seiler FR (1978) Stimulatory effect of Vibrio cholerae neuraminidase on the antibody response against various antigens. Immunology 34:181–187PubMedGoogle Scholar
  5. 5.
    Leyden VE von, Blumenthal F (1902) Vorläufige Mitteilungen über einige Ergebnisse der Krebsforschung auf der 1. medizinischen Klinik. Dtsch Med Wochenschr 28:637–638CrossRefGoogle Scholar
  6. 6.
    Mackaness GB, Lagrange PH, Miller TE, Ishibashi T (1974) The formation of activated T-cells. In: Wagner WH, Hahn H, Evans R (eds) Activation of macrophages. Excerpta Medica, Amsterdam, pp 193–209Google Scholar
  7. 7.
    Mathé G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hay at M, DeVassal F (1969) Active immunotherapy for acute lymphoblastic leukemia. Lancet 1:697–699PubMedCrossRefGoogle Scholar
  8. 8.
    Oettgen MD (1977) Immunotherapy of cancer. N Engl J Med 297:484–491PubMedCrossRefGoogle Scholar
  9. 9.
    Romeis B (1968) Mikroskopische Technik, 16th edn. Oldenbourg, Munich, p 339–341Google Scholar
  10. 10.
    Ronneberger H (1978) Toxicological studies with therapeutically applicable Vibrio cholerae neuraminidase. Dev Biol Stand 38:413–419Google Scholar
  11. 11.
    Ruddel CL (1967) Embedding media for 1–2 micron sectioning. 2. Hydroxyethyl methacrylate combined with 2-butoxyethanol. Stain Technol 42:253–255Google Scholar
  12. 12.
    Sanford BH (1967) An alteration in tumor histocompatibility induced by neuraminidase. Transplantation 5:1273–1279PubMedCrossRefGoogle Scholar
  13. 13.
    Schick HJ, Zilg H (1978) Production and quality control of therapeutically applicable Vibrio cholerae neuraminidase (VCN). Dev Biol Stand 38:81–85Google Scholar
  14. 14.
    Sedlacek HH, Seiler FR (1974) Demonstration of Vibrio cholerae neuraminidase (VCN) on the surface of VCN-treated cells. Behring Inst Mitt 55:254–257Google Scholar
  15. 15.
    Sedlacek HH, Seiler FR (1977) The effect of Vibrio cholerae neuraminidase (VCN) on the local and humoral immunological reaction of mice against SRBC. Z Immunitaetsforsch 153:35Google Scholar
  16. 16.
    Sedlacek HH, Seiler FR (1978) Immunotherapy of neoplastic diseases with neuraminidase: Contradictions, new aspects and revised concepts. Cancer Immunol Immunother 5:153–163CrossRefGoogle Scholar
  17. 17.
    Sedlacek HH, Weise M, Lemmer A, Seiler FR (1979) Immunotherapy of spontaneous mammary tumors in mongrel dogs with autologous tumor cells and neuraminidase. Cancer Immunol Immunother 6:47–58CrossRefGoogle Scholar
  18. 18.
    Weiss L (1965) Studies on cell deformability. I. Effect of surface charge. J Cell Biol 26:735–739PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • F. R. Seiler
  • H.-H. Sedlacek

There are no affiliations available

Personalised recommendations